Eurocine Vaccines strengthens the organization for further development
Eurocine Vaccines strengthens the organization with necessary competence, not only to prepare for further development of its first product, the nasal influenza vaccine candidate Immunose™ FLU,Read…
Eurocine Vaccines strengthens the organization for further development
“In parallel with finalizing the analyses and evaluation of the current study, we now prepare for the next steps of development. Reinforcing the organization withRead…
Eurocine Vaccines expects clinical results June/July 2017
Eurocine Vaccines expects results from the ongoing immunological analyses in June/July 2017. The samples presently being analyzed were collected during the clinical study on theRead…
Eurocine Vaccines expects clinical results June/July 2017
“I am pleased that the progress of the immunological analyses has been somewhat faster than expected”, said CSO Dr. Anna-Karin Maltais.”Read More
Högt tempo på BIO Europe Spring 2017
Nya behandlingsformer, högt tempo och barnvacciner präglade årets första stora Europeiska konferens, BIO Europe Spring 2017. Ett flertal nya kontakter knöts och befintliga relationer stärktes.Read…
Högt tempo på BIO Europe 2017
Nya behandlingsformer, högt tempo och barnvacciner präglade årets första stora Europeiska konferens, BIO Europe 2017. Ett flertal nya kontakter knöts och befintliga relationer stärktes. PåRead…
Tålamod på Bio ASIA 2017
Eurocine Vaccines VD Hans Arwidsson hann med att såväl knyta värdefulla kontakter som att följa upp tidigare relationer under partneringmötena på årets konferens Bio ASIA.Read…
Tålamod på Bio ASIA 2017
Eurocine Vaccines VD Hans Arwidsson hann med att såväl knyta värdefulla kontakter som att följa upp tidigare relationer under partneringmötena på årets konferens BIO Asia.Read…
Eurocine Vaccines´ nasal influenza vaccine candidate Immunose™ FLU showed good safety in clinical study
Eurocine Vaccines today announced that Immunose™ FLU, a quadrivalent influenza vaccine candidate showed good safety in a clinical phase I/II study. Immunose™ FLU is a novelRead…
Eurocine Vaccines´ nasal influenza vaccine candidate Immunose™ FLU showed good safety in clinical study
The trial was primarily designed to study the safety and tolerability of Immunose™ FLU in healthy adults, 18-39 years of age. The clinical phase of theRead…